02 November 2026

ASX Supervision
Level 45, South Tower, Rialto
525 Collins Street
Melbourne VIC 3000

By email: listingssupervisionmelbourne@asx.com.au.

RESPONSE TO PRICE QUERY

4DMedical Limited ("4DX" or the "Company") responds to the letter received from the Australian Securities Exchange ("ASX") dated 30 October 2026 in regard to a price query.

In reference to the questions listed in the ASX letter:

1. **Is 4DX aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?**

   No. The Company is not aware of any information that has not been announced which, if known, could be an explanation for the recent trading in the securities.

2. **If the answer to question 1 is 'yes'.**
   a) **Is 4DX relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in 4DX's securities would suggest to ASX that such information may have ceased to be confidential and therefore 4DX may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.**
   b) **Can an announcement be made immediately? Please note, if the answer to this question is 'no', you need to contact us immediately to discuss requesting a trading halt (see below).**
   c) **If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?**

   Not applicable.

3. **If the answer to question 1 is 'no', is there any other explanation that 4DX may have for the recent trading in its securities?**

   To the best of its knowledge, the Company believes an increase in short interest is responsible for the recent trading in its securities.

4. **Please confirm that 4DX is complying with the Listing Rules and, in particular, Listing Rule 3.1.**

   Yes. The Company is complying with the ASX Listing Rules and, in particular, Listing Rule 3.1.

5. **Please confirm that 4DX's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an**

For personal use only

Melbourne Office:
Level 7 Melbourne Connect
700 Swanston Street
CARLTON VIC 3053
AUSTRALIA
Tel: +61 (3) 9545 5940

Los Angeles Office:
21255 Burbank Boulevard
Suite 120
WOODLAND HILLS CA 91367
USA
Tel: +1 (818) 403 8490

4dmedical.com
info@4dmedical.com

officer of 4DX with delegated authority from the board to respond to ASX on disclosure matters.

Yes. The Company confirms that its responses to the questions above have been authorised and approved by the Chair and the Chief Executive Officer on behalf of the Board, in accordance with the Company's published Continuous Disclosure Policy.

Yours sincerely

Hamish George
Company Secretary

For personal use only

For personal use only

30 October 2026

Mr Hamish George
Company Secretary
4DMedical Limited
Level 7, 700 Swanston Street
Carlton, Victoria 3053

By email: hamish.george@bio101.com

Dear Mr George

4DMedical Limited ('4DX'): Price Query

ASX refers to the following:

A. The change in the price of 4DX's securities from a high of $3.28 at close of trade on 29/10/2026 to a low of $2.41 today.

B. The significant increase in the volume of 4DX's securities traded today.

Request for information

In light of this, ASX asks 4DX to respond separately to each of the following questions and requests for information:

1. Is 4DX aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

2. If the answer to question 1 is 'yes'.

   (a) Is 4DX relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in 4DX's securities would suggest to ASX that such information may have ceased to be confidential and therefore 4DX may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.

   (b) Can an announcement be made immediately? Please note, if the answer to this question is 'no', you need to contact us immediately to discuss requesting a trading halt (see below).

   (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?

3. If the answer to question 1 is 'no', is there any other explanation that 4DX may have for the recent trading in its securities?

4. Please confirm that 4DX is complying with the Listing Rules and, in particular, Listing Rule 3.1.

5. Please confirm that 4DX's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of 4DX with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **9:30 AM AEDT Monday, 2 November 2026**.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, 4DX's

obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require 4DX to request a trading halt immediately.

Your response should be sent by e-mail to **listingssupervisionmelbourne@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow us to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in 4DX's securities under Listing Rule 17.1. If you wish to request a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts and Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in 4DX's securities under Listing Rule 17.3.1.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to 4DX's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*. It should be noted that 4DX's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A. The usual course is for correspondence to be released to the market.

For personal use only

Kind regards

ASX Supervision

For personal use only